Stay updated on Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page.

Latest updates to the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page displays the ClinicalTrials.gov record for a completed Phase 2 study of tislelizumab combined with fruquintinib, including study results, eligibility criteria, locations, and supporting documents.SummaryDifference59%

- Check16 days agoChange DetectedThe footer shows site revision v3.8.0 instead of v3.7.2; the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check23 days agoChange DetectedA sitewide NIH notice appears above the page, announcing a transition from the term “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check30 days agoChange DetectedThe footer’s site revision label changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site revision displayed in the footer changed from v3.7.0 to v3.7.1, while the page continued to show a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now shows a 403 Forbidden error, indicating access to the study record is blocked. This reflects an error condition rather than an update to the study data or page structure.SummaryDifference19%

Stay in the know with updates to Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page.